Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EPIX 
ESSA Pharma Inc (EPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/08/2025: EPIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.74
1 Year Target Price $1.74
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.87% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.52M USD | Price to earnings Ratio - | 1Y Target Price 1.74 |
Price to earnings Ratio - | 1Y Target Price 1.74 | ||
Volume (30-day avg) 2 | Beta 1.53 | 52 Weeks Range 0.18 - 6.45 | Updated Date 10/14/2025 |
52 Weeks Range 0.18 - 6.45 | Updated Date 10/14/2025 | ||
Dividends yield (FY) 87.56% | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.25% | Return on Equity (TTM) -21.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -99334904 | Price to Sales(TTM) - |
Enterprise Value -99334904 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.09 | Shares Outstanding 47308394 | Shares Floating 33355729 |
Shares Outstanding 47308394 | Shares Floating 33355729 | ||
Percent Insiders 5.62 | Percent Institutions 73.7 |
Upturn AI SWOT
ESSA Pharma Inc
Company Overview
History and Background
ESSA Pharma Inc. is a pharmaceutical company focused on developing novel therapies for prostate cancer. Founded in 2009, it has progressed from early-stage research to clinical trials, targeting the androgen receptor (AR) signaling pathway.
Core Business Areas
- NME Development: ESSA Pharma focuses on developing novel molecular entities (NMEs) for treating prostate cancer.
- Clinical Trials: The company conducts clinical trials to assess the safety and efficacy of its drug candidates.
Leadership and Structure
ESSA Pharma has a management team led by a CEO, supported by a board of directors. The organizational structure comprises research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- EPI-7386: EPI-7386 is ESSA Pharma's lead clinical candidate, an N-terminal domain (NTD) inhibitor of the androgen receptor. It is being developed for castration-resistant prostate cancer (CRPC). Market share data is not currently available due to its developmental stage. Competitors include companies developing AR inhibitors, such as ARASAZ (ORIC).
Market Dynamics
Industry Overview
The prostate cancer treatment market is substantial and growing, driven by aging populations and improved diagnostics. Key areas include hormonal therapies, chemotherapy, and targeted therapies.
Positioning
ESSA Pharma aims to address limitations of current AR-targeting therapies by developing an NTD inhibitor. Its advantage lies in potentially overcoming resistance mechanisms.
Total Addressable Market (TAM)
The global prostate cancer market is projected to reach billions of USD. ESSA is positioned to capture a segment of this market with its novel therapeutic approach.
Upturn SWOT Analysis
Strengths
- Novel NTD inhibitor mechanism
- Clinical-stage asset (EPI-7386)
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources relative to larger pharma companies
- High risk associated with clinical development
- Reliance on a single lead asset
Opportunities
- Potential to address unmet needs in CRPC
- Partnerships with larger pharmaceutical companies
- Expansion into other AR-driven cancers
- Positive clinical trial results driving market value
Threats
- Competition from established therapies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
Competitive Landscape
ESSA Pharma faces competition from established players with approved therapies and larger R&D budgets. Its competitive advantage lies in its novel mechanism of action and potential to address resistance.
Growth Trajectory and Initiatives
Historical Growth: ESSA Pharma's growth is marked by progressing its lead asset through clinical development.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization or partnership opportunities.
Recent Initiatives: Recent initiatives include advancing EPI-7386 in clinical trials and exploring combination therapies.
Summary
ESSA Pharma is a clinical-stage company with a promising drug candidate for prostate cancer, offering a novel mechanism of action. Its strengths include its unique approach and strong intellectual property. Key risks include clinical trial outcomes and competition, necessitating strategic partnerships and financial planning.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Investor presentations, Press releases, Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ESSA Pharma Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2015-07-09 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.essapharma.com |
Full time employees 35 | Website https://www.essapharma.com | ||
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.